Nuclear Medicine and Cancer Theragnostics
Authors:
- Vasiliki ZoiVZVasiliki Zoi
- Maria GiannakopoulouMGMaria Giannakopoulou
- George A AlexiouGeorge A Alexiou
- Pinelopi BouziotisPBPinelopi Bouziotis
- Savvas ThalasselisSTSavvas Thalasselis
- Andreas G TzakosAndreas G Tzakos
- Andreas FotopoulosAFAndreas Fotopoulos
- Athanassios P KyritsisAKAthanassios P Kyritsis
- Chrissa SiokaChrissa Sioka
Preprint
- 12 September 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Cancer theragnostics is a novel approach that combines diagnostic imaging and radionuclide therapy. It is based on the use of a pair of radiopharmaceuticals, one optimized for positron emission tomography imaging, through linkage to a proper radionuclide, and the other bearing a beta-emitter isotope that can induce significant damage to cancer cells. In recent years, the use of theragnostics in nuclear medicine clinical practice has increased considerably, and thus investigation has focused on the identification of novel radionuclides that can bind to molecular targets which are typically dysregulated in different cancers. The major advantages of the theragnostic approach include elimination of multi-step procedures, reduced adverse effects to normal tissues, early diagnosis, better predicting responses and personalized patient care. This review aims to discuss emerging theragnostic molecules that have been investigated in a series of human malignancies, including gliomas, thyroid cancer, neuroendocrine tumors, cholangiocarcinoma and prostate cancer, as well as potent and recently introduced molecular targets, like cell-surface receptors, kinases, and cell adhesion proteins. Furthermore, special reference has been made to copper radionuclides as theragnostic agents, and their radiopharmaceutical applications since they present promising alternatives to the well-studied gallium-68 and lutetium-177.Keywords
All Related Versions
- Version 1, 2023-09-12, Preprints
- Published version: Diagnostics, 13 (19), 3064.
This publication has 94 references indexed in Scilit:
- [18F]MFBG PET/CT outperforming [123I]MIBG SPECT/CT in the evaluation of neuroblastomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2023
- Cadherin‐3 is a novel oncogenic biomarker with prognostic value in glioblastomaMolecular Oncology, 2021
- Ga-68 PSMA PET/CT in recurrent high-grade gliomas: evaluating PSMA expression in vivoNeuroradiology, 2021
- Improving staging of rectal cancer in the pelvis: the role of PET/MRIEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020
- Clinical utility of 177Lu‐DOTATATE PRRT in somatostatin receptor‐positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicityHead & Neck, 2019
- New developments in the production of theranostic pairs of radionuclidesJournal of Radioanalytical and Nuclear Chemistry, 2018
- 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experienceEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology settingCancer Chemotherapy and Pharmacology, 2011
- Expression of Prostate‐Specific Membrane Antigen in Normal and Malignant Human TissuesWorld Journal of Surgery, 2006
- Radioiodine therapy for papillary and follicular thyroid carcinomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002